<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567539</url>
  </required_header>
  <id_info>
    <org_study_id>1394</org_study_id>
    <nct_id>NCT02567539</nct_id>
  </id_info>
  <brief_title>Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma</brief_title>
  <official_title>Phase II Study of Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate efficacy and safety of re-irradiation for patients with
      recurrent high grade gliomas after other treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators designed this study of a re-irradiation with single radiosurgery or
      hypofractionated intensity modulated radiation therapy (IMRT) with or without temozolomide.

      Objective of the study is evaluating efficacy and safety of re-irradiation for patients with
      recurrent high grade gliomas after other treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free of participants</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival of participants</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of radionecrosis</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire assessment of neurocognitive function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Recurrent High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>Recurrent high grade glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT with or without radiosensitive therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT with or without radiosensitive therapy</intervention_name>
    <description>Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc</description>
    <arm_group_label>Recurrent high grade glioma</arm_group_label>
    <other_name>Hypofractionated Stereotactic Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiosensitive therapy</intervention_name>
    <description>Radiosensitive therapy with Temozolomide</description>
    <arm_group_label>Recurrent high grade glioma</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Karnosky performance status (KPS) ≥70

          -  Patients aged &gt;70 years with KPS ≥80

          -  Histopathologically confirmed grade III-IV glioma

          -  Estimated survival ≥ 3 months

          -  Any Tumor volume

          -  Unifocal tumor

          -  Interval time from previous radiotherapy ≥ 6mesi

          -  Normal liver, Kidney and bone marrow function

          -  Written informed consent

        Exclusion Criteria:

          -  KPS &lt; 70

          -  Multifocal tumor

          -  Other primary cancer

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piera Navarria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piera Navarria, MD</last_name>
    <phone>+390282247458</phone>
    <email>piera.navarria@cancercenter.humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annamaria Ascolese, MD</last_name>
    <phone>+390282247456</phone>
    <email>anna_maria.ascolese@cancercenter.humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piera Navarria, MD</last_name>
      <phone>+390282247458</phone>
      <email>piera.navarria@cancercenter.humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Annamaria Ascolese, MD</last_name>
      <phone>+390282247456</phone>
      <email>anna_maria@cancercenter.humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Piera Navarria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federico Pessina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Scorsetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Bello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annamaria Ascolese, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Navarria P, Ascolese AM, Tomatis S, Reggiori G, Clerici E, Villa E, Maggi G, Bello L, Pessina F, Cozzi L, Scorsetti M. Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge. Cancer Res Treat. 2016 Jan;48(1):37-44. doi: 10.4143/crt.2014.259. Epub 2015 Feb 23.</citation>
    <PMID>25761491</PMID>
  </results_reference>
  <results_reference>
    <citation>Scorsetti M, Navarria P, Pessina F, Ascolese AM, D'Agostino G, Tomatis S, De Rose F, Villa E, Maggi G, Simonelli M, Clerici E, Soffietti R, Santoro A, Cozzi L, Bello L. Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. BMC Cancer. 2015 Jun 30;15:486. doi: 10.1186/s12885-015-1488-2.</citation>
    <PMID>26118437</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

